ZA989745B - Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction - Google Patents
Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interactionInfo
- Publication number
- ZA989745B ZA989745B ZA989745A ZA989745A ZA989745B ZA 989745 B ZA989745 B ZA 989745B ZA 989745 A ZA989745 A ZA 989745A ZA 989745 A ZA989745 A ZA 989745A ZA 989745 B ZA989745 B ZA 989745B
- Authority
- ZA
- South Africa
- Prior art keywords
- beta
- interaction
- app
- inhibiting
- amyloid peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9713384A FR2770217B1 (fr) | 1997-10-24 | 1997-10-24 | Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA989745B true ZA989745B (en) | 1999-05-04 |
Family
ID=9512632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA989745A ZA989745B (en) | 1997-10-24 | 1998-10-26 | Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction |
Country Status (8)
Country | Link |
---|---|
AT (1) | ATE521630T1 (es) |
DK (1) | DK1025121T3 (es) |
ES (1) | ES2372586T3 (es) |
FR (1) | FR2770217B1 (es) |
PL (1) | PL198079B1 (es) |
PT (1) | PT1025121E (es) |
SI (1) | SI1025121T1 (es) |
ZA (1) | ZA989745B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE286971T1 (de) * | 1991-01-21 | 2005-01-15 | Elan Pharm Inc | Prüfung und modell für alzheimers-krankheit |
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
JP2000506375A (ja) * | 1996-01-26 | 2000-05-30 | エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ | アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用 |
-
1997
- 1997-10-24 FR FR9713384A patent/FR2770217B1/fr not_active Expired - Fee Related
-
1998
- 1998-10-23 DK DK98951547.3T patent/DK1025121T3/da active
- 1998-10-23 ES ES98951547T patent/ES2372586T3/es not_active Expired - Lifetime
- 1998-10-23 PT PT98951547T patent/PT1025121E/pt unknown
- 1998-10-23 AT AT98951547T patent/ATE521630T1/de active
- 1998-10-23 SI SI9830931T patent/SI1025121T1/sl unknown
- 1998-10-23 PL PL340054A patent/PL198079B1/pl not_active IP Right Cessation
- 1998-10-26 ZA ZA989745A patent/ZA989745B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
FR2770217B1 (fr) | 2001-12-07 |
DK1025121T3 (da) | 2011-11-28 |
ATE521630T1 (de) | 2011-09-15 |
ES2372586T3 (es) | 2012-01-24 |
PL198079B1 (pl) | 2008-05-30 |
PL340054A1 (en) | 2001-01-15 |
PT1025121E (pt) | 2011-11-04 |
SI1025121T1 (sl) | 2011-12-30 |
FR2770217A1 (fr) | 1999-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wait et al. | Strategies for proteomics with incompletely characterized genomes: the proteome of Bos taurus serum | |
Deibler et al. | Chromatographic fractionation of myelin basic protein: Partial characterization and methylarginine contents of the multiple forms | |
Simon et al. | The glutamine residues reactive in transglutaminase-catalyzed cross-linking of involucrin. | |
Lozier et al. | Complete amino acid sequence of human plasma beta 2-glycoprotein I. | |
McKeehan et al. | Purification and partial characterization of the aminoacyl transfer ribonucleic acid binding enzyme from rabbit reticulocytes | |
Dingwall et al. | A polypeptide domain that specifies migration of nucleoplasmin into the nucleus | |
Garrels | Changes in protein synthesis during myogenesis in a clonal cell line | |
Trüeb et al. | Type VI collagen is composed of a 200 kd subunit and two 140 kd subunits. | |
Suchanek et al. | Translation of melittin messenger RNA in vitro yields a product terminating with glutaminylglycine rather than with glutaminamide. | |
Bromer et al. | Amino acid sequence of bovine glucagon | |
Fischer‐Colbrie et al. | Isolation and characterization of chromogranins A, B, and C from bovine chromaffin granules and a rat pheochromocytoma | |
McDonald et al. | Mitochondrial proteomics: Undercover in the lipid bilayer | |
Chang et al. | Studies on the status of free amino and carboxyl groups in cobrotoxin | |
Kreil | Biosynthesis of Melittin, a Toxic Peptide from Bee Venom: Amino‐Acid Sequence of the Precursor | |
ATE208816T1 (de) | Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5 | |
Champion et al. | A two‐dimensional protein map of Chinese hamster ovary cells | |
CA2273196A1 (en) | Isolated mammalian monocyte cell genes; related reagents | |
Changchien et al. | The function of the N-terminal region of ribosomal protein S4 | |
MXPA94006367A (es) | Gene novedoso. | |
Hogue-Angeletti | Subunit structure and amino acid composition of xylose isomerase from Streptomyces albus. | |
Beard et al. | Studies on Marsupial Proteins V. Amino Acid Sequence of the?-Chain of Haemoglobin From the Grey Kangaroo, Macropus Giganteus | |
Walker et al. | The Subunits of Rabbit‐Muscle Phosphofructokinase: A Search for Sequence Repetition | |
Metters et al. | Selective cleavage of proenkephalin-derived peptides (less than 23,300 daltons) by plasma kallikrein. | |
ZA989745B (en) | Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction | |
Edmunds et al. | Role of ATP hydrolysis in the degradation of proteins by protease La from Escherichia coli |